冠轈控股(01872.HK)料中期純利將大幅減少
格隆匯 6 月 30日丨冠轈控股(01872.HK)發佈公告,截至2020年5月31日止五個月,公司權益持有人應占集團溢利較2019年同期大幅減少約56%(已撇除上市開支的影響),主要是由於新加坡衞生部為遏制COVID-19進一步擴散而實施安全距離措施,導致集團於2020年4月7日至2020年6月18日(包括首尾兩天)期間臨時關閉展廳,致使收益大幅減少。
基於上述財務資料及公司目前可得資料,考慮到(i)疫情尚未結束;及(ii)集團的展廳自2020年4月7日起臨時關閉且於2020年6月19日方重新開業,董事會預計,截至2020年6月30日止六個月,公司權益持有人應占集團溢利將較2019年同期大幅減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.